Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 56073. Отображено 100.
05-01-2012 дата публикации

Enterovirus Vaccines for Preventing or Treating Type 1 Diabetes (III)

Номер: US20120003240A1
Принадлежит: Sanofi Pasteur Inc, Vactech OY

Coxsackie B virus CBV1 has been found to be strongly associated with the risk of contracting type 1 diabetes. A vaccine comprising CBV1, a component thereof or an antibody thereto is provided for use in preventing or treating type 1 diabetes. In addition CBV2 was also found to be diabetogenic.

Подробнее
05-01-2012 дата публикации

Immunogenic compositions for inducing an immune response to hiv

Номер: US20120003265A1
Принадлежит: WYETH LLC

The invention relates to immunogenic compositions for inducing an immune response to HIV comprising combinations of two, three, or four plasmids, where each plasmid is expressing a defined antigen, which may be a single antigen or a fusion of two or three antigens.

Подробнее
10-08-2009 дата публикации

УСТРОЙСТВО ДЛЯ ПОЛУЧЕНИЯ ВИРИОНОВ ВИРУСОВ КЛЕЩЕВОГО ЭНЦЕФАЛИТА ИЛИ БЕШЕНСТВА

Номер: RU0000085480U1

1. Устройство для получения вирионов вирусов клещевого энцефалита или бешенства из инактивированной вируссодержащей суспензии, содержащее вместилище с корпусом из материала, не взаимодействующего с вирионами клещевого энцефалита и бешенства, заполненное поперечно-сшитой 4-6% агарозой. 2. Устройство по п.1, отличающееся тем, что вместилище заполнено агарозой марок Sepharose 4 Fast Flow или Sepharose 6 Fast Flow. 3. Устройство по п.1 или 2, отличающееся тем, что вместилище выполнено в виде полого цилиндра. РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 85 480 U1 (51) МПК C12N 7/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ, ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ (12) ОПИСАНИЕ ПОЛЕЗНОЙ МОДЕЛИ К ПАТЕНТУ (21), (22) Заявка: 2009105546/22, 18.02.2009 (24) Дата начала отсчета срока действия патента: 18.02.2009 (45) Опубликовано: 10.08.2009 (73) Патентообладатель(и): Набатников Павел Алексеевич (RU), Ворович Михаил Фридрихович (RU), Киктенко Александр Васильевич (RU), Белов Михаил Юрьевич (RU) U 1 8 5 4 8 0 R U Ñòðàíèöà: 1 ru CL U 1 Формула полезной модели 1. Устройство для получения вирионов вирусов клещевого энцефалита или бешенства из инактивированной вируссодержащей суспензии, содержащее вместилище с корпусом из материала, не взаимодействующего с вирионами клещевого энцефалита и бешенства, заполненное поперечно-сшитой 4-6% агарозой. 2. Устройство по п.1, отличающееся тем, что вместилище заполнено агарозой марок Sepharose 4 Fast Flow или Sepharose 6 Fast Flow. 3. Устройство по п.1 или 2, отличающееся тем, что вместилище выполнено в виде полого цилиндра. 8 5 4 8 0 (54) УСТРОЙСТВО ДЛЯ ПОЛУЧЕНИЯ ВИРИОНОВ ВИРУСОВ КЛЕЩЕВОГО ЭНЦЕФАЛИТА ИЛИ БЕШЕНСТВА R U Адрес для переписки: 127221, Москва, ул. Полярная, 8, кв. 165, М.Ф. Воровичу (72) Автор(ы): Набатников Павел Алексеевич (RU), Ворович Михаил Фридрихович (RU), Киктенко Александр Васильевич (RU), Белов Михаил Юрьевич (RU) RU 5 10 15 20 25 30 35 40 45 50 85 480 U1 Полезная модель относится к биотехнологии, в частности, к ...

Подробнее
20-09-2010 дата публикации

УСТРОЙСТВО ДЛЯ ПОЛУЧЕНИЯ ВИРИОНОВ ХАНТАВИРУСОВ ИЗ ВИРУССОДЕРЖАЩЕЙ СУСПЕНЗИИ

Номер: RU0000097729U1

1. Устройство для поучения вирионов хантавирусов из вируссодержащей суспензии, включающее заполненное сорбентом вместилище, корпус которого выполнен из материала, не взаимодействующего с вирионами хантавирусов, отличающееся тем, что вместилище заполнено агарозой марки Sepharose 6 Fast Flow. 2. Устройство по п.1, отличающееся тем, что вместилище выполнено в виде полого цилиндра. Ц 97729 ко РОССИЙСКАЯ ФЕДЕРАЦИЯ 7 ВУ” 97729 44 ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ИЗВЕЩЕНИЯ К ПАТЕНТУ НА ПОЛЕЗНУЮ МОДЕЛЬ ММ9К Досрочное прекращение действия патента из-за неуплаты в установленный срок пошлины за поддержание патента в силе Дата прекращения действия патента: 12.11.2018 Дата внесения записи в Государственный реестр: 13.08.2019 Дата публикации и номер бюллетеня: 13.08.2019 Бюл. №23 Стр.: 1 61416 па П

Подробнее
12-01-2012 дата публикации

Transfection of blood cells with mrna for immune stimulation and gene therapy

Номер: US20120009221A1
Принадлежит: CureVac AG

The present invention relates to a pharmaceutical composition containing blood cells or haemopoietic cells, e.g. red blood cells (erythrocytes), granulocytes, mononuclear cells (PBMCs) and/or blood platelets, in combination with a pharmaceutically acceptable excipient and/or vehicle, wherein the cells are transfected with at least one mRNA comprising at least one region coding for at least one antigen. The invention further discloses a method of preparing the aforesaid pharmaceutical composition and the use of blood cells transfected in this way for the preparation of drugs or pharmaceutical compositions for immune stimulation against the antigens encoded by the mRNA. The subjects according to the invention are used especially for the therapy and/or prophylaxis of carcinoses or infectious diseases and can also be employed in gene therapy.

Подробнее
19-01-2012 дата публикации

Avirulent, immunogenic flavivirus chimeras

Номер: US20120014981A1

Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.

Подробнее
16-02-2012 дата публикации

Methods and systems for reducing viral load of hepatitis c virus in hemodialysis patients

Номер: US20120037564A1
Принадлежит: Aethlon Medical Inc

The present technology relates to methods and systems for the removal of pathogens and fragments thereof in hemodialysis patients. In particular, methods and systems are described where lectins can be used to remove the Hepatitis C virus and fragments thereof in hemodialysis patients, and to provide a sustained reduction in viral load.

Подробнее
16-02-2012 дата публикации

Compositions and methods for vaccine and virus production

Номер: US20120039939A1
Принадлежит: JOHNS HOPKINS UNIVERSITY

The present invention features methods of producing immunogenic compositions and viruses, methods of treating and preventing viral infection, and methods of producing an immune response using cells that express a polypeptide selected from the group consisting of: cdk13, siat7e, Iama4, cox15, egr1, gas6, map3k9, and gap43, and a virus.

Подробнее
16-02-2012 дата публикации

Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish

Номер: US20120040010A1
Принадлежит: Individual

The invention relates to a composition and a method for manufacturing semi-dry or dry particles containing a mucoadhesive polymer and a bioactive agent such as, but not limited to, an Immunogenic Substance (e.g., a vaccine), that allows the oral or nasal administration and delivery of the bioactive agent essentially unaltered to mucosal surfaces in the animal, including an aquatic animal.

Подробнее
16-02-2012 дата публикации

Identification of Porcine Reproductive and Respiratory Syndrome Virus

Номер: US20120040335A1
Принадлежит: South Dakota State University

An enzyme-linked immunosorbent assay (ELISA) is based on the non-structural protein 7 (nsp7) of porcine reproductive and respiratory syndrome virus (PRRSV) and provides for the simultaneous detection and differentiation of serum antibodies directed against Type 1 (European) and Type 2 (North American) PRRSV. The invention provides a serological assay for the detection and/or differentiation of serum antibodies directed against Type 1 and/or Type 2 PRRSV utilizing PRRSV nsp7 as an antigen, and provides a diagnostic method for the detection of PRRSV infection, epidemiological surveys, and outbreak investigations. The invention may be used either alone or as a follow-up assay to determine the true status of unexpected positive results that may occur using other assays, such as the IDEXX HERDCHEK PRRS ELISA.

Подробнее
23-02-2012 дата публикации

Biomolecule Surface Display and Uses Thereof

Номер: US20120045473A1
Автор: Jimmy Kwang
Принадлежит: Temasek Life Sciences Laboratory Ltd

A vaccine for the treatment or prevention of a disease in a subject, wherein said disease is associated with an avian influenza virus, and wherein said vaccine comprises an expression vector comprising a nucleic acid encoding a hemagglutinin peptide, such that in use said hemagglutinin peptide is expressed by said expression vector in said subject.

Подробнее
08-03-2012 дата публикации

Adenoviral va1 pol iii expression system for rnai expression

Номер: US20120058522A1
Принадлежит: CITY OF HOPE

An adenoviral VA1 Pol III expression system for RNAi expression is provided.

Подробнее
15-03-2012 дата публикации

Tetravalent influenza vaccine and use thereof

Номер: US20120064117A1
Принадлежит: University of Pittsburgh

Disclosed herein is the finding that baculovirus display of multiple influenza virus hemagglutinin (HA) proteins elicits broadly reactive immune responses against influenza. Thus provided herein are recombinant baculovirus vectors having a first, second, third and fourth nucleic acid sequence, each encoding an influenza hemagglutinin (HA) fusion protein. The first, second, third and fourth nucleic acid sequences each encode an influenza HA with a different amino acid sequence. Also provided are recombinant baculoviruses displaying a first, second, third and fourth influenza virus HA fusion protein in the baculovirus envelope, wherein each HA fusion protein comprises a different HA amino acid sequence. Tetravalent influenza virus vaccines comprising the recombinant baculoviruses disclosed herein are further provided. In addition, methods of immunizing a subject against influenza virus using the tetravalent influenza virus vaccines are provided. In particular examples of the compositions and methods disclosed herein, the HA polypeptides are from H5N1 influenza virus.

Подробнее
15-03-2012 дата публикации

Dengue vaccine, pharmaceutical composition comprising the same, and nucleotide sequence

Номер: US20120065373A1
Автор: Yee-Shin Lin
Принадлежит: National Cheng Kung University NCKU

The present invention relates to a dengue vaccine, a pharmaceutical composition including the same, and a nucleotide sequence. The dengue vaccine includes N and C termini-deleted nonstructural protein ΔNC NS1 with a peptide fragment from amino acids 36 to 270, which is derived from dengue virus nonstructural protein 1 (DV NS1) with deletions of N-terminal region from amino acids 1 to 35 and C-terminal region from amino acids 271 to 352. The dengue vaccine of the present invention is depleted of cross-reactivity with endothelial cells and platelets, and can shorten the bleeding time.

Подробнее
22-03-2012 дата публикации

Compositions and methods for identifying enzyme and transport protein inhibitors

Номер: US20120071344A1
Автор: Roland Wolkowicz

The invention is directed to compositions, e.g., cell-based and multiplexed platforms, to screen for small molecule drugs that inhibit enzymes such as proteases, e.g., viral proteases, e.g., HIV proteases; and methods for making and using these compositions. The invention provides compositions and methods for identifying compositions, e.g., drug molecules, that can inhibit proteases, e.g., viral proteases such as HIV proteases. In alternative embodiments, the invention provides cell-based platforms or assays to screen for compositions, e.g., small molecules or drugs, that inhibit or modify the activity of enzymes such as calcium-dependent protein convertases involved in HIV envelope protein processing, including cleavage of the HIV gp160 envelope precursor, resulting in gp120 and gp41 envelope products. In one embodiment, the invention provides a cell-based or multiplexed platform for monitoring the activity of enzymes, e.g., proteases such as viral proteases.

Подробнее
29-03-2012 дата публикации

Separation Of Virus And/Or Protein From Nucleic Acids By Primary Amines

Номер: US20120077249A1
Принадлежит: Millipore Corp

A method of purifying biomolecules with an anion exchanger containing a membrane having a surface having a polymer such as a primary or secondary amine ligand formed thereon, such as polyallylamine. The feedstock is introduced to the exchanger in the presence of one or more ionic-modifiers by themselves or in combination with monovalent salt. The ionic modifier alters the binding ability of the primary amines such that they retain a significant binding capacity for highly charged species such as DNA but lose part or almost all of their binding capacity for less charged species such as viruses or proteins at pH above the pI of the virus or protein.

Подробнее
29-03-2012 дата публикации

Animal-free cell culture method

Номер: US20120077268A1
Принадлежит: GLAXOSMITHKLINE BIOLOGICALS SA

The present invention relates to a process for culturing animal cells, e.g., human, diploid anchorage-dependent cells, in the absence of exogenous components of primary animal origin. In particular, the invention provides cell culture media substantially free of exogenous components of primary and secondary animal origin which comprises at least one, more preferably several, exogenous animal-free growth factors. The present invention also relates to a process for cultivating animal cells using a protease of non-animal origin for passaging cells.

Подробнее
29-03-2012 дата публикации

Materials and Methods for the Treatment of Pathological Neovascularization in the Eye

Номер: US20120077870A1

The subject invention provides materials and methods useful in safely and effectively preventing pathological proliferation of blood vessels. The prevention of the over-proliferation of blood vessels according to the subject invention is particularly advantageous for treatment of certain ocular conditions including age-related macular degeneration (AMD), retinopathy of prematurity (ROP) and diabetic retinopathy. In preferred embodiments, the subject invention provides materials and methods for effective treatment of pathological ocular neovascularization using gene therapy. In a specific embodiment the materials and methods of the subject invention can be used to treat AMD.

Подробнее
19-04-2012 дата публикации

Process for producing poxviruses and poxvirus compositions

Номер: US20120093780A1
Принадлежит: TRANSGENE SA

The present invention relates to compositions and pharmaceutical compositions comprising poxviruses and more particularly extracellular enveloped viruses. The present invention also relates to a process for producing poxviruses and poxviruses obtained thereof. Moreover, the present invention also relates to the use of said poxvirus and said composition for the preparation of a medicament.

Подробнее
19-04-2012 дата публикации

RSV F VLPs AND METHODS OF MANUFACTURE AND USE THEREOF

Номер: US20120093855A1
Автор: Joel R. Haynes
Принадлежит: Ligocyte Pharmaceuticals Inc

The present invention relates to the field of isolation of enveloped virus-based virus-like particles (VLPs) free of infectious agents. In preferred examples, the field includes methods of inactivation of infectious agents that do not adversely affect the immunogenicity of the enveloped virus-based VLPs. In certain embodiments, the enveloped virus-based VLPs are produced in insect cell based expression systems.

Подробнее
19-04-2012 дата публикации

Hcv vaccines and methods for using the same

Номер: US20120093863A1

Improved anti-HCV immunogens and nucleic acid molecules that encode them are disclosed. Immunogens disclosed include those having consensus HCV genotype 1a, including for example, NS4B, NS5A and NS5B. Pharmaceutical composition, recombinant vaccines comprising and live attenuated vaccines are disclosed as well methods of inducing an immune response in an individual against HCV are disclosed.

Подробнее
03-05-2012 дата публикации

Composition useful as rotavirus vaccine and a method therefor

Номер: US20120107356A1
Принадлежит: Bharat Biotech International Ltd

Compositions and methods related to live or live attenuated pre-conditioned and typical viruses such as rotaviruses are disclosed. The live attenuated rotaviruses exhibit better stability characteristics and are useful for the prevention of a rotavirus infection and/or rotavirus gastroenteritis in children.

Подробнее
03-05-2012 дата публикации

Novel divergent picornavirus: cosavirus

Номер: US20120107357A1
Принадлежит: BLOOD SYSTEMS Inc

Presented herein is the discovery of a new human picornavirus, Cosavirus (previously termed Dekavirus), methods of detecting the Cosavirus and diagnosing Cosavirus infection, methods of treating or preventing Cosavirus infection, and methods for identifying anti-Cosavirus compounds.

Подробнее
03-05-2012 дата публикации

Recombinant envelope protein of human immunodeficiency virus (hiv) and vaccine containing the same

Номер: US20120107910A1
Автор: George Dacai Liu
Принадлежит: Individual

The present invention provides a recombinant HIV Env antigenic protein, a virus-like particle and a recombinant HIV virus. The present invention further provides a vaccine comprising the recombinant HIV Env antigenic protein, the virus-like particle or recombinant HIV virus.

Подробнее
17-05-2012 дата публикации

TAT Protein for preventing or treating AIDS

Номер: US20120121632A9
Автор: Erwann Loret

The invention relates to a method of preventing or treating acquired immunodeficiency syndrome (AIDS) in a patient, wherein the patient is administered with a Tat protein comprising amino acid sequence SEQ ID NO: 1 or 2, or a variant thereof capable of stimulating an immune response against Tat proteins.

Подробнее
17-05-2012 дата публикации

Hiv cd4 binding site based covalent immunogen compositions

Номер: US20120121633A1
Принадлежит: Individual

Provided are immunogenic compositions based on the highly conserved, core CD4 binding site of the gp120 protein of the human immunodeficiency virus. One embodiment includes an antigenic conjugate of an electophilic derivative of HIV gp120 peptide 416-433, designated E-416-433, covalently linked to an immunogenic carrier protein. The compositions are effective in stimulating the production of HIV neutralizing antibodies in mammals. Provided also are related methods of immunization, methods of antibody production and antibodies obtained using the methods of the invention.

Подробнее
17-05-2012 дата публикации

Method to enhance an immune response of nucleic acid vaccination

Номер: US20120121690A1
Принадлежит: Lipoxen Technologies Ltd

A composition comprising liposomes associated with a nucleic acid operatively encoding an antigenic protein and with an assistor protein, wherein the assistor protein shares at least one epitope with the antigenic protein, and wherein the nucleic acid and said assistor protein are associated with the same liposomes is described. The composition provides an improved immune response compared to mixtures of liposomes some of which are associated with the nucleic acid and some of which are associated with the assistor protein.

Подробнее
17-05-2012 дата публикации

Viral Infection Enhancing Peptide

Номер: US20120122177A1
Принадлежит: Individual

The invention relates to a peptide derived from HIV-1 gp120 which forms insoluble aggregates when introduced into an aqueous solution and its use for enhancing viral infection of cells. In addition, the invention comprises methods for enhancing viral infection of cells, for concentrating a virus and for separating a virus from a fluid.

Подробнее
31-05-2012 дата публикации

Human matrix metalloproteinase-8 gene delivery enhances the oncolytic activity of a replicating adenovirus

Номер: US20120134964A1
Принадлежит: New York University NYU

The present invention discloses a method of treating cancer in a subject. This involves co-administering a replicating virus and a matrix metalloproteinase to the subject under conditions effective to treat cancer. It also relates to a method of enhancing the delivery to and distribution within a tumor mass of therapeutic viruses. This involves co-administering a replicating virus and a matrix metalloproteinase to the tumor mass under conditions effective to enhance the delivery to and distribution within the tumor mass of therapeutic viruses. Another aspect relates to a cancer therapeutic. This involves a replicating virus and a matrix metalloproteinase.

Подробнее
07-06-2012 дата публикации

Norovirus and sapovirus antigens

Номер: US20120141529A1
Принадлежит: Individual

Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus , coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus - or Sapovirus -derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described. The immunogenic compositions of the invention may also contain antigens other than Norovirus or Sapovirus antigens, including antigens that can be used in immunization against pathogens that cause diarrheal diseases, such as antigens derived from rotavirus.

Подробнее
07-06-2012 дата публикации

Fusion proteins of hiv regulatory/accessory proteins

Номер: US20120142097A1
Принадлежит: Individual

The invention relates to fusion proteins comprising the amino acid sequence of at least three HIV proteins selected from Vif, Vpr, Vpu, Rev, and Tat or derivatives of the amino acid sequence of one or more of said proteins, wherein the fusion protein is not processed to individual HIV proteins having the natural N and C termini. The invention further concerns nucleic acids encoding said proteins, vectors comprising said nucleic acids, and methods for producing said proteins. The fusion protein, nucleic acids and vectors are usable as vaccines for the at least partial prophylaxis against HIV infections.

Подробнее
28-06-2012 дата публикации

Chimeric molecules

Номер: US20120164155A1
Автор: Elizabeth Grgacic

The invention relates to chimeric proteins comprising an antigen and a trimer forming portion or a trimer and virus-like particle forming portion of foamy virus envelope protein (FV TM). The trimer or trimer and virus-like particle forming portion comprises i) full length foamy virus transmembrane protein; ii) foamy virus transmembrane protein absent a functional cytoplasmic domain; iii) foamy virus transmembrane protein absent a functional cytoplasmic domain and transmembrane domain; iv) foamy virus ectodomain comprising N-terminal heptad repeat region and cysteine rich region between N-terminal heptad repeat region and C-terminal α-helical region; v) N-terminal heptad repeat region; vi) a functional variant of any one of i) to v); or vii) any one of i) to vi) lacking an FV fusion peptide domain. In particular, the antigen is an antigen of a virus envelope protein, such as HIV gp 120. Soluble and membrane bound forms of trimeric and higher oligomeric forms of the chimeric proteins are provided as well as nucleic acid molecules encoding and expressing same, viral-like particles comprising same, compositions including pharmaceutical compositions, host cells and kits. Methods are described for producing immune responses including antibodies determined by the chimeric protein or VLP, as well as methods of screening using the chimeric protein, VLP and/or antibodies.

Подробнее
05-07-2012 дата публикации

Reagents and methods for modulating cone photoreceptor activity

Номер: US20120172419A1

The present invention provides reagents and methods for modulating cone photoreceptor activity, and devices for assessment of cone photoreceptor activity.

Подробнее
12-07-2012 дата публикации

Lipid vesicle compositions and methods of use

Номер: US20120177724A1
Принадлежит: Massachusetts Institute of Technology

The invention provides delivery systems comprised of stabilized multilamellar vesicles, as well as compositions, methods of synthesis, and methods of use thereof. The stabilized multilamellar vesicles comprise terminal-cysteine-bearing antigens or cysteine-modified antigens, at their surface and/or internally.

Подробнее
19-07-2012 дата публикации

Continuous culture apparatus with mobile vessel, allowing selection of fitter cell variants and producing a culture in a continuous manner

Номер: US20120184009A1
Принадлежит: Individual

A method and device for growing plant, animal or stem cells in a continuous manner.

Подробнее
26-07-2012 дата публикации

Attenuated pestiviruses

Номер: US20120189659A1
Автор: Gregor Meyers
Принадлежит: BOEHRINGER INGELHEIM VETMEDICA GMBH

This invention relates to attenuated pestiviruses characterised in that their enzymatic activity residing in glycoprotein E RNS is inactivated, as well as methods of preparing, using and detecting these pestiviruses.

Подробнее
02-08-2012 дата публикации

Polyanionic polymer adjuvants for haemophilus influenzae b saccharide vaccines

Номер: US20120195937A1
Принадлежит: GLAXOSMITHKLINE BIOLOGICALS SA

The present invention relates to immunogenic compositions comprising capsular polysaccharide or oligosaccharide of H. influenzae B (PRP) and methods of making such compositions.

Подробнее
09-08-2012 дата публикации

Materials and methods for assay of anti-hepatitis c virus (hcv) antibodies

Номер: US20120202295A1
Принадлежит: ABBOTT LABORATORIES

A polypeptide comprising the contiguous amino acids 1-198 of SEQ ID NO: 2; a polypeptide, which comprises a contiguous amino acid sequence that is at least about 95% identical to the contiguous amino acids 1-198 of SEQ ID NO: 2, an epitope that is immunoreactive with an antibody that specifically binds to the core protein of hepatitis C virus (HCV), and an epitope that is immunoreactive with an antibody that specifically binds to the NS4 region of HCV; a nucleic acid encoding such a polypeptide; a host cell comprising such a nucleic acid; an immunodiagnostic reagent comprising such a polypeptide; a kit comprising such an immunodiagnostic reagent; and a method of determining the presence, amount, or concentration of anti-HCV antibodies in a test sample.

Подробнее
23-08-2012 дата публикации

Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps

Номер: US20120213817A1
Автор: Joel R. Haynes
Принадлежит: Ligocyte Pharmaceuticals Inc

The present invention relates to chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus GAG-based virus-like particles (VLPs). The present invention also includes methods of making and using such chimeric VLPs. In certain embodiments, the GAG polypeptide of the chimeric VLPs comprises an HIV or ALV GAG polypeptide.

Подробнее
06-09-2012 дата публикации

Methods of propagating monkey adenoviral vectors

Номер: US20120225470A1
Принадлежит: Genvec Inc

The invention provides methods for propagating a monkey adenovirus in a cell including a human cell, comprising one or more gene products isolated from a human adenovirus. Also provided are methods for propagating wherein the monkey adenovirus comprises a nucleic acid sequence encoding a human adenovirus gene product. The invention further provides a monkey adenovirus. including a replication-deficient monkey adenovirus, obtained by such propagation methods.

Подробнее
20-09-2012 дата публикации

Production of viral vaccines in suspension on avian embryonic derived stem cell lines

Номер: US20120238001A1
Принадлежит: Vivalis SA

The present invention relates to the development and manufacturing of viral vaccines. In particular, the invention relates to the field of industrial production of viral vectors and vaccines, more in particular to the use of avian embryonic stem cells, preferably the EBx® cell line derived from chicken embryonic stem cells, for the production of viral vectors and viruses. The invention is particularly useful for the industrial production of viral vaccines to prevent viral infection of humans and animals.

Подробнее
27-09-2012 дата публикации

Adenovirus Infection In Animals

Номер: US20120244187A1
Автор: Richard L. Atkinson
Принадлежит: Obetech LLC

Animals have tested positive for unsuspected natural infection with lipogenic adenoviruses. Methods for testing animals, including food stuffs and experimental animals, for lipogenic adenovirus infection are disclosed. Exposure to infected meat and animal co-products may cause health and safety issues. As a result of lipogenic adenovirus infection in experimental animal species, research related to fat or glucose metabolism, energy metabolism, cancer biology, and obesity research may have been or may be negatively affected or compromised.

Подробнее
27-09-2012 дата публикации

Methods for identifying a virulent strain of a virus

Номер: US20120244521A1
Автор: Gennadi V. Glinsky
Принадлежит: Individual

The present invention relates to methods for identifying a virulent strain of a virus, particularly and influenza virus, by detecting specific mutations in the amino acid sequence of the hemagglutinin (HA) protein and by determining the case fatality rate for hospitalization (CFR/H) as the number of persons hospitalized for infection by the virus who die from the infection compared to the total number of persons hospitalized for infection, wherein the identification of mutations in the HA protean and/or an increasing CFR/H over time indicates a virulent strain of the virus.

Подробнее
25-10-2012 дата публикации

Adjuvated Influenza Vaccine and Use Thereof

Номер: US20120269852A1
Принадлежит: Abbott Biologicals BV

A viral vaccine, specifically an influenza vaccine, comprises a combination of a component (a1) represented by a detoxified or non-toxic mutant of subunit A of an AB type exotoxin, and a component (a2) represented by at least one substance selected from the group consisting of metal salts and mineral salts, in association with a viral immunogen.

Подробнее
25-10-2012 дата публикации

Reverse genetics systems

Номер: US20120270321A1
Принадлежит: NOVARTIS AG

The invention provides various reverse genetics systems for producing segmented RNA viruses, wherein the systems do not require bacteria for propagation of all of their expression constructs.

Подробнее
08-11-2012 дата публикации

Functional mutation in respiratory syncytial virus

Номер: US20120282673A1
Автор: Bin Lu, HONG Jin, Robert Brazas
Принадлежит: MEDIMMUNE LLC

The present invention provides recombinant respiratory syncytial viruses that have an attenuated phenotype and that comprise one or more mutations in the viral P, M2-1 and/or M2-2 proteins, as well as live attenuated vaccines comprising such viruses and nucleic acids encoding such viruses. Recombinant RSV P, M2-1 and M2-2 proteins are described. Methods of producing attenuated recombinant RSV, and methods of quantitating neutralizing antibodies that utilize recombinant viruses of family Paramyxoviridae, are also provided.

Подробнее
29-11-2012 дата публикации

Method of using adenoviral vectors to induce an immune response

Номер: US20120302627A1

The invention provides a method of inducing an immune response against a human immunodeficiency virus (HIV) in a mammal. The method comprises administering to the mammal an adenoviral vector composition comprising one or more adenoviral vectors encoding two or more different HIV antigens, the production of which induces an immune response against HIV in the mammal. The invention also provides an adenoviral vector composition comprising four adenoviral vectors encoding an HIV clade A Env protein, an HIV clade B Env protein, an HIV clade C Env protein, and a fusion protein comprising an HIV clade B Gag protein and Pol protein, respectively.

Подробнее
27-12-2012 дата публикации

Compositions and methods for vaccinating against hsv-2

Номер: US20120328656A1
Принадлежит: UNIVERSITY OF WASHINGTON, Vical Inc

This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from herpes simplex virus. Also disclosed are therapeutic compositions useful in such a method.

Подробнее
27-12-2012 дата публикации

Methods and compositions for the production of recombinant virus vectors

Номер: US20120329136A1
Автор: Weidong Xiao
Принадлежит: Individual

A method for the production of a replication-deficient recombinant virus vector is disclosed. The replication-deficient recombinant virus vector has a recombinant virus genome with one or more defective viral genes. The method comprises infecting a host cell with a carrier virus having a carrier virus genome encoding one or more trans factors or variants thereof, incubating the infected host cell for a desired period of time, and isolating the replication-deficient recombinant virus vector. The carrier virus is a cytoplasmic virus that retains the carrier virus genome in the cytoplasm of the host cell. The host cell contains the recombinant viral genome and retains the recombinant viral genome in a nucleus of the host cell. Also disclosed is a carrier virus for the production of a replication-deficient recombinant virus vector.

Подробнее
27-12-2012 дата публикации

Pathogen Restriction Factors

Номер: US20120331576A1

The use of interferon induced transmembrane protein 1, 2, or 3 (IFITM1, 2, or 3) as a viral restriction factor, and methods of using the same to produce virus, transgenic animals expressing exogenous IFITM1, 2, or 3, and methods of treating or inhibiting viral infections by targeting a gene identified herein

Подробнее
03-01-2013 дата публикации

Process for manufacturing vaccines

Номер: US20130004532A1
Принадлежит: GLAXOSMITHKLINE BIOLOGICALS SA

The present application discloses an improved method for conducting saccharide—protein conjugation reactions using carbodiimide condensation chemistry. Depending on the nature of the saccharide or protein carrier involved, the quality of the conjugate may be improved by adding one of the reaction components slowly to the reaction mixture. Immunogenic compositions are further provided comprising the saccharide-protein conjugates made by the methods disclosed.

Подробнее
07-02-2013 дата публикации

Reverse genetics methods for virus rescue

Номер: US20130034582A1
Принадлежит: NOVARTIS AG

A method for rescuing a virus by reverse genetics is provided in which cells are added after transfection.

Подробнее
07-02-2013 дата публикации

Compositions, methods and uses for expression of enterobacterium-associated peptides

Номер: US20130034583A1
Принадлежит: Inviragen Inc

Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing enterobacterial-associated peptides. In some embodiments, enterobacterial-associated peptides include, but are not limited to plague-associated peptides. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, attenuated or modified vaccinia virus vectors expressing enterobacterial-associated peptides. In other embodiments, vaccine compositions are reported of use in a subject.

Подробнее
14-02-2013 дата публикации

Hbv drug resistance methods

Номер: US20130040284A1
Принадлежит: Innogenetics NV SA

New polymorphisms in the nucleic acid sequences of the DNA polymerase/reverse transcriptase open reading frame and viral surface antigen open reading frame of the hepatitis B virus are reported. In particular, the present invention relates to the mutation YMDD→YSDD in the HBV reverse transcriptase domain and to the W196V mutation in the small HBV viral surface antigen. Said polymorphisms are affecting the detection of drug resistance mutations by genotypic methods and diagnostic kits based thereon. The present invention relates to methods and diagnostic kits for detection of a HBV virus comprising said nucleic acid polymorphisms. In particular, those methods utilizing oligonucleotides capable of hybridizing to said HBV nucleic acid polymorphisms are envisaged.

Подробнее
28-02-2013 дата публикации

Preparation method of virus expressing alpha-galactose epitope and vaccine

Номер: US20130052219A1

A method for producing an α-Gal-expressing virus having enhanced immune response to viruses, without requiring the use of any enzyme; an influenza virus vaccine having a high effect (antigenicity), which is produced using an α-Gal-expressing virus produced by the method; and others. Specifically disclosed are: a method for producing an α-galactose epitope (Galα1-3Galβ1-4GlcNAc-R: α-Gal hereinafter)-expressing virus, which comprises the steps of: (1) introducing an α1,3- galactosyltransferase gene in an expressible condition into a cell line that does not express α-Gal to obtain a cell line capable of expressing α-Gal; (2) inoculating a virus into the cell line capable of expressing α-Gal to obtain a cell line infected with a virus; and (3) culturing the cell line infected with the virus to obtain a virus expressing α-Gal from the culture medium..

Подробнее
28-02-2013 дата публикации

Jfh-1 based hcv cell culture systems for ns5a of genotypes 1-7

Номер: US20130052716A1
Принадлежит: HVIDOVRE HOSPITAL, KOBENHAVNS UNIVERSITET

The present inventors developed hepatitis C virus recombinants expressing NS5A from genotype 1a, 1b, 2a, 3a, 4a, 5a, 6a or 7a in the context of a genotype 2a backbone. Additional recombinants express NS5A and the structural proteins (Core, E1 and E2), p7 and NS2 from genotype 1a, 1b, 3a, 4a, 5a, 6a or 7a in the genotype 2a backbone. Sequence analysis of the recombinants recovered after viral passage in Huh7.5 cells revealed adaptive mutations in NS5A and/or NS3. The importance of these mutations for improved growth kinetics was shown in reverse genetic studies.

Подробнее
07-03-2013 дата публикации

Adeno-associated virus serotype i nucleic acid sequences, vectors and host cells containing same

Номер: US20130059289A1
Принадлежит: University of Pennsylvania Penn

The nucleic acid sequences of adeno-associated virus (AAV) serotype 1 are provided, as are vectors and host cells containing these sequences and functional fragments thereof. Also provided are methods of delivering genes via AAV-1 derived vectors.

Подробнее
21-03-2013 дата публикации

Recombinant Herpes Virus and Pharmaceutical Composition Containing The Same

Номер: US20130071355A1
Принадлежит:

An object of the present invention is to provide a highly-safe recombinant herpes virus showing high antitumor activity regardless of the kind, grade of malignancy, or growth rate of tumor cells. 1. A recombinant herpes simplex virus in which the endogenous ICP6 gene is deleted or inactivated and comprising , on the genome of the virus , an expression cassette constructed to express an ICP6 gene under control of a tumor-specific promoter or tissue-specific promoter.2. The recombinant herpes simplex virus according to claim 1 , wherein the endogenous ICP6 gene has been inactivated by inserting the expression cassette in the endogenous ICP6 gene.3. The recombinant herpes simplex virus according to claim 1 , wherein the expression cassette has been inserted into a deletion site of the endogenous ICP6 gene.4. The recombinant herpes simplex virus according to claim 1 , wherein the expression cassette has been inserted in a direction opposite to the direction of the endogenous ICP6 gene.5. A recombinant herpes simplex virus comprising an endogenous ICP6 gene functionally linked to a tumor-specific promoter or tissue-specific promoter.6. The recombinant herpes simplex virus according to claim 1 , wherein the tumor-specific promoter or tissue-specific promoter is a promoter selected from the group consisting of a human telomerase reverse transcriptase (hTERT) promoter claim 1 , a PSES promoter claim 1 , and an osteocalcin (OC) promoter;7. The recombinant herpes simplex virus according to claim 1 , wherein a γ34.5 gene and/or an ICP47 gene is also deleted or inactivated.8. A pharmaceutical composition comprising the recombinant herpes simplex virus as claimed in as an active ingredient.9. The pharmaceutical composition according to claim 8 , which is a therapeutic agent for a tumor.10. The pharmaceutical composition according to claim 9 , wherein the tumor is a tumor selected from the group consisting of tumors with a low growth rate claim 9 , benign tumors claim 9 , and ...

Подробнее
21-03-2013 дата публикации

Bunyavirus vaccine

Номер: US20130071429A1
Принадлежит: University of St Andrews

The present invention provides attenuated viruses for use as vaccines and for the treatment and/or prevention of viral diseases and/or infections.

Подробнее
21-03-2013 дата публикации

MICRORNA-CONTROLLED RECOMBINANT VACCINIA VIRUS AND USE THEREOF

Номер: US20130071430A1
Принадлежит: THE UNIVERSITY OF TOKYO

It is intended to provide a vaccinia virus that specifically proliferates in a cancer cell and destroys the cancer cell and to provide use of the virus in cancer treatment. The present invention provides a microRNA-controlled vaccinia virus, in which a target sequence of a microRNA less expressed in a cancer cell than in a normal cell is inserted in a 3′ untranslated region of B5R gene associated with viral proliferation in a vaccinia virus, wherein the microRNA-controlled vaccinia virus specifically proliferates in the cancer cell and has an oncolytic property that destroys the cancer cell. 1. A microRNA-controlled vaccinia virus , in which a target sequence of a microRNA less expressed in a cancer cell than in a normal cell is inserted in a 3′ untranslated region of B5R gene associated with viral proliferation in a vaccinia virus , wherein the microRNA-controlled vaccinia virus specifically proliferates in the cancer cell and has an oncolytic property that specifically destroys the cancer cell.2. The microRNA-controlled vaccinia virus according to claim 1 , wherein the microRNA expressed in the normal cell represses the expression of the B5R gene to reduce the proliferative capacity of the microRNA-controlled vaccinia virus in the normal cell.3. The microRNA-controlled vaccinia virus according to or claim 1 , wherein the B5R gene into which the microRNA target sequence is inserted in its 3′ untranslated region is introduced into an attenuated vaccinia virus lacking a portion or the whole of its B5R gene.4. The microRNA-controlled vaccinia virus according to or claim 1 , wherein the vaccinia virus is an LC16 strain or an LC16mO strain.5. The microRNA-controlled vaccinia virus according to claim 3 , wherein the vaccinia virus is an LC16m8 strain lacking a portion of its B5R gene or an m8Δ strain lacking the whole of its B5R gene.6. The microRNA-controlled vaccinia virus according to claim 1 , wherein the microRNA less expressed in a cancer cell than in a normal cell ...

Подробнее
21-03-2013 дата публикации

Method for Preserving Polypeptides Using A Sugar and Polyethyleneimine

Номер: US20130071431A1
Принадлежит: Stabilitech Ltd.

The invention relates to the preservation of an active agent, such as a polypeptide, by contacting the active agent with a preservation mixture including a sugar and polyethyleneimine. 1. A method for preserving a polypeptide comprising:(i) providing an aqueous solution of one or more sugars, a polyethyleneimine and said polypeptide; and(ii) drying the solution to form an amorphous solid matrix comprising said polypeptide.2. The method according to wherein the concentration of polyethyleneimine is 25 μM or less based on the number-average molar mass (M) of the polyethyleneimine and the sugar concentration or claim 1 , if more than one sugar is present claim 1 , total sugar concentration is greater than 0.1M claim 1 , and the method optionally further comprises providing the resulting dried amorphous solid matrix in the form of a powder in a sealed vial claim 1 , ampoule claim 1 , or syringe.3. The method according to in which{'sub': n', 'n, '(a) the Mof the polyethyleneimine is between 20 and 1000 kDa and the concentration of the polyethyleneimine is between 0.001 and 100 nM based on the M, and/or'}{'sub': n', 'n, '(b) the Mof the polyethyleneimine is between 1 and 10000 Da and the concentration of the polyethyleneimine is between 0.0001 and 1004 based on the M, and/or'}(c) the said concentration of polyethyleneimine is 20 μM or less or less than 500 nM, and/or(d) the said concentration of polyethyleneimine is 0.025 nM or more or 0.1 nM or more, and/or(e) the said concentration of polyethyleneimine is between 0.1 nM and 5 μM or between 0.1 nM and 200 nM.4. The method according to in which(a) the sugar concentration, or total sugar concentration, is between 0.5 and 2M; and/or(b) the sugar is sucrose, stachyose, raffinose or a sugar alcohol, or(c) two or more sugars are present in said aqueous solution, or{'sub': 'n', '(d) two or more sugars are present in said aqueous solution and wherein sucrose is present with another sugar; the concentration of sucrose relative to ...

Подробнее
21-03-2013 дата публикации

Compositions And Methods For Immunodominant Antigens of Mycobacterium Tuberculosis

Номер: US20130072398A1

Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen M. tuberculosis and their use in vaccines, therapeutic agents, and various diagnostic tests. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter.

Подробнее
28-03-2013 дата публикации

ENVELOPED VIRUS VACCINE AND METHOD FOR PRODUCTION

Номер: US20130078261A1
Принадлежит: Baxter Healthcare S.A.

The present invention provides methods of production of a purified enveloped virus antigen. In particular, it provides purified Ross River Virus (RRV) antigens, and vaccines comprising purified, inactivated Ross River Virus (RRV) antigen. 1. A preparation comprising purified Ross River Virus antigen being free of contaminating protein from the cells or the cell culture and has less than 10 pg cellular nucleic acid/μg virus antigen.2. The preparation according to claim 1 , further comprising a physiologically acceptable carrier.3. The preparation according to claim 1 , further comprising an adjuvant.4. A vaccine against Ross River Virus infection comprising a host protective amount of a purified Ross River Virus antigen claim 1 , wherein said vaccine is substantially free of any contaminating protein from the cells or the cell culture and has an amount of cellular nucleic acid per vaccine dose of less than 10 pg/μg antigen.5. The vaccine according to claim 4 , wherein said host protective amount of Ross River Virus antigen is between about 0.1 and about 50 μg/dose.6. The vaccine according to claim 4 , further comprising an adjuvant.7. A method of immunizing a mammal against Ross River Virus infection comprising the steps of providing a vaccine comprising a host protective amount of Ross River Virus antigen claim 4 , wherein said vaccine is substantially free of any contaminating protein from the cells or the cell culture and has an amount of cellular DNA of less than about 10 pg/μg antigen claim 4 , and administering said vaccine to a mammal.8. A method for the preparation of an immune globulin preparation specific against Ross River Virus comprising the steps of (i) immunizing a mammal with a vaccine according to and (ii) isolating from the serum of the immunized mammal the immune globulin fraction comprising the RRV specific antibodies. This application is a continuation of U.S. application Ser. No. 11/657,848, filed Jan. 24, 2007 which is a division of U.S. patent ...

Подробнее
28-03-2013 дата публикации

Infectious hepatitis c virus-high producing hcv variants and use thereof

Номер: US20130078277A1

An objective of this invention is to provide an HCV strain with a high capacity for virus production in a cell culture system. This invention provides a nucleic acid encoding a polyprotein precursor of the hepatitis C virus JFH1 strain having one or more amino acid substitutions, wherein the polyprotein precursor comprises at least substitution of glutamine at position 862 with arginine, as determined with reference to the amino acid sequence as shown in SEQ ID NO: 2 in the Sequence Listing.

Подробнее
04-04-2013 дата публикации

Method for the identification of t cell epitopes

Номер: US20130085260A1

A novel method to identify relevant T-cell epitopes recognized by CD8 + or CD4 − T lymphocytes is described. The method is based on the use of mRNA fragments synthesized from cDNA encoding portions of a polypeptide of interest. mRNA fragments are introduced into antigen-presenting cells to deduce an epitope's localization in a polypeptide of interest, such as a protein antigen.

Подробнее
11-04-2013 дата публикации

Dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications

Номер: US20130089558A1

The present invention relates to the development of viral vectors expressing different immunogens from the West Nile Encephalitis Virus (WNV) or the Dengue virus which are able to induce protective humoral and cellular immune responses against WNV or Dengue virus infections. More specifically, the present invention relates to three (3) antigens from WNV (the secreted envelope glycoprotein (E), the heterodimer glycoproteins (pre-M-E) and the NSI protein) and from Dengue virus (the secreted envelope glycoprotein (e), the heterodimer glycoproteins (pre-m-e) and the nsl protein) and their use in vaccinal, therapeutic and diagnostic applications.

Подробнее
18-04-2013 дата публикации

STABILIZED VIRUS LIKE PARTICLES HAVING ENHANCED MUCOSAL IMMUNOGENICITY

Номер: US20130095134A1

This disclosure relates to compositions and methods for inducing immune response. Specifically, the disclosure relates to a composition comprising a subunit antigen stabilized by a polysaccharide-containing plant extract, in which the antigen consists of virus-like particles that have enhanced mucosal immuno-genicity as a result of the stabilization. 1. A composition comprising a dry powder containing a subunit antigen comprising virus-like particles , wherein said subunit antigen is stabilized by a polysaccharide-containing plant extract.2. The composition of claim 1 , wherein said virus-like particles are from a virus selected from the group consisting of human papillomavirus virus claim 1 , hepatitis B virus claim 1 , Influenza virus claim 1 , and a norovirus.3. The composition of claim 1 , wherein the virus-like particles are from a norovirus capsid protein (NoVCP).4. The composition of claim 3 , wherein the norovirus virus is selected from the group consisting of norovirus genotype I claim 3 , norovirus genotype II claim 3 , norovirus genotype III or norovirus genotype IV.5. The composition of claim 4 , wherein the norovirus virus is a GI genotype.6. The composition of claim 1 , wherein the plant extract is an Aloe plant extract.7. The composition of claim 1 , wherein the composition is substantially free of adjuvants such as TLR agonists.8. The composition of claim 1 , wherein the virus-like particles comprise an antigen selected from the group consisting of human papillomavirus L1 and L2 proteins claim 1 , hepatitis B core protein (HBcAg) claim 1 , hepatitis B surface antigen (HBSAg) claim 1 , hepatitis C core protein (HCcAg) and a combination of one or more of influenza hemagglutinin (HA) claim 1 , influenza neuraminidase (NA) claim 1 , and influenza matrix 1 (M1) proteins.9. The composition of claim 1 , wherein the anionic polysaccharide is a low-methoxy pectin claim 1 , Xanthan claim 1 , carboxymethylcellulose claim 1 , alginate or their combination.10. ...

Подробнее
18-04-2013 дата публикации

Tetravalent Dengue Vaccines

Номер: US20130095136A1
Автор: Guirakhoo Farshad
Принадлежит: Sanofi Pasteur Biologics, LLC

The invention provides tetravalent Dengue vaccines, and methods of using these vaccines to prevent or to treat Dengue infection. 1. A method of inducing an immune response to the four serotypes of dengue virus in a patient , the method comprising administering to the patient a vaccine comprising:a chimeric flavivirus comprising the capsid and non-structural proteins of Yellow Fever virus and the pre-membrane and envelope proteins of Dengue-1 virus;a chimeric flavivirus comprising the capsid and non-structural proteins of Yellow Fever virus and the pre-membrane and envelope proteins of Dengue-2 virus;a chimeric flavivirus comprising the capsid and non-structural proteins of Yellow Fever virus and the pre-membrane and envelope proteins of Dengue-3 virus; anda chimeric flavivirus comprising the capsid and non-structural proteins of Yellow Fever virus and the pre-membrane and envelope proteins of Dengue-4 virus.2. The method of claim 1 , wherein all four chimeras are administered at equivalent concentrations.3. The method of claim 2 , wherein each chimera is administered at a concentration of 5 logPFU.4. The method of claim 2 , wherein each chimera is administered at a concentration of 4 logPFU.5. The method of claim 1 , wherein the Dengue-1 and Dengue-2 chimeras are administered at an amount that is greater than that of the Dengue-3 and Dengue-4 chimeras.6. The method of claim 5 , wherein said Dengue-1 and Dengue-2 chimeras are administered at 5 logPFU and said Dengue-3 and Dengue-4 chimeras are administered at 4 logPFU.7. The method of claim 5 , wherein said Dengue-1 and Dengue-2 chimeras are administered at 5 logPFU and said Dengue-3 and Dengue-4 chimeras are administered at 3 logPFU.8. The method of claim 5 , wherein said Dengue-1 and Dengue-2 chimeras are administered at 4 logPFU and said Dengue-3 and Dengue-4 chimeras are administered at 3 logPFU.9. The method of claim 1 , wherein said patient does not have claim 1 , but is at risk of developing claim 1 , Dengue ...

Подробнее
18-04-2013 дата публикации

Norovirus and sapovirus antigens

Номер: US20130095552A1
Принадлежит: Novartis Vaccines and Diagnostics Inc

Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described. The immunogenic compositions of the invention may also contain antigens other than Norovirus or Sapovirus antigens, including antigens that can be used in immunization against pathogens that cause diarrheal diseases, such as antigens derived from rotavirus.

Подробнее
18-04-2013 дата публикации

NOVEL VESICULAR STOMATITIS VIRUS AND VIRUS RESCUE SYSTEM

Номер: US20130095556A1
Принадлежит: International AIDS Vaccine Initiative

The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines as well as the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention. 1. A vesicular stomatitis virus (VSV) genomic clone comprising:(a) a VSV genome encoding and expressing a nucleocapsid, phosphoprotein, matrix, glycoprotein and large protein, wherein the VSV genome comprises nucleotide substitutions and amino acid coding changes to improve replicative fitness and genetic stability,(b) a cloning vector,(c) an extended T7 promoter,(d) a hammerhead ribozyme,(e) a hepatitis delta virus ribozyme and T7 terminator(f) unique restriction endonuclease cleavage sites in a VSV genomic sequence(g) a leader and a trailer that are cis-acting sequences controlling mRNA synthesis and replication2. The VSV genomic clone of claim 1 , wherein the cloning vector is pSP72 (Genbank X65332.2)3. The VSV genomic clone of claim 1 , wherein the extended T7 promoter is PT7-g10.4. The VSV genomic clone of claim 1 , wherein the unique restriction endonuclease cleavage sites are 1367 NheI claim 1 , 2194 SpeI claim 1 , 2194 BstBI claim 1 , 4687 PacI claim 1 , 7532 AvaI claim 1 , 10190 SalI and 11164 AflII.5. The VSV genomic clone of claim 1 , wherein the VSV genomic clone is depicted in .6. The VSV genomic clone of claim 1 , wherein the nucleotide position is according to GenBank Accession Number EF197793 and wherein the nucleotide substitutions are selected from the group consisting of1371 CA>GC (NheI)After 2195 insert TAG (SpeI) (all genome numbers below adjusted to include +3 bp)3036 G>T improves match to consensus transcription stop signal3853 X>A (was an ambiguity in Genbank file)4691 T>A to generate PacI7546 C>A silent change in L coding sequence eliminates a BstBI site1960 TAC>TCC to change Y>S3247 GTA>ATA to change V>I3729 AAG>GAG to change K>E4191 GTA>GAA to change V>E4386 GGT>GAT to change G>D4491 ACC ...

Подробнее
25-04-2013 дата публикации

CHIMPANZEE ADENOVIRAL VECTOR-BASED FILOVIRUS VACCINES

Номер: US20130101618A1
Принадлежит:

This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV). 1. A method of inducing an immune response against a filovirus antigen in a subject , the method comprising administering to the subject an immunologically effective amount of a recombinant adenovirus vector comprising a nucleic acid encoding a filovirus antigenic protein , wherein the adenovirus vector comprises a chimpanzee adenovirus capsid protein.2. The method of claim 1 , wherein the adenovirus vector is administered intramuscularly.3. The method of claim 1 , wherein the step of administering comprises a priming vaccination followed by a boosting vaccination.4. The method of claim 1 , wherein the adenovirus vector comprising a chimpanzee capsid protein is a common chimpanzee adenovirus vector.5. The method of claim 4 , wherein the common chimpanzee adenovirus vector is selected from the group consisting of a ChAd3 vector and a ChAd63 vector.6. The method of claim 1 , wherein the adenovirus vector comprising a chimpanzee capsid protein is a bonobo chimpanzee adenovirus vector.7. The method of claim 6 , wherein the bonobo chimpanzee adenovirus vector is a PanAd3 vector.8. The method of claim 1 , wherein the filovirus antigenic protein is a glycoprotein.9. The method of claim 1 , wherein the filovirus antigenic protein is from an Ebola virus.10. The method of claim 9 , wherein the Ebola virus is of species Zaire.11. The method of claim 10 , wherein the filovirus antigenic protein is encoded by a polynucleotide sequence as shown in SEQ ID NO:10 (Z GP wild-type).12. The method of claim 9 , wherein the Ebola virus is of species Sudan/Gulu.13. The method of claim 12 , wherein the filovirus antigenic protein is encoded by a polynucleotide sequence as ...

Подробнее
25-04-2013 дата публикации

Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens

Номер: US20130101619A1
Принадлежит: Intervet Inc

The present invention discloses novel recombinant multivalent non-pathogenic Marek's Disease virus constructs that encode and express both Infectious Laryngotracheitis Virus and Newcastle Disease virus protein antigens, and methods of their use in poultry vaccines.

Подробнее
25-04-2013 дата публикации

Recombinant varicella-zoster virus

Номер: US20130101620A1

A recombinant varicella-zoster virus; a process for producing the same; a pharmacological composition containing recombinant varicella-zoster virus; a vector containing a genomic gene of varicella-zoster virus and BAC vector sequence; cells containing the above vector; a fragment capable of homologous recombination with a genome of varicella-zoster virus; and a nucleic acid cassette containing the BAC vector sequence. For these, there is provided a process for producing recombinant varicella-zoster virus, comprising use of the BAC vector sequence.

Подробнее
25-04-2013 дата публикации

In Vitro Method for obtaining Intrahepatic Fibroblasts Infected with Hepatitis C Virus

Номер: US20130101986A1

The present invention relates to in vitro methods for obtaining intrahepatic fibroblasts infected with hepatitis C virus, to the infected intrahepatic fibroblasts obtained by means of these methods, and also to methods for screening for anti-fibrogenesis molecules and for anti-HCV molecules using these cells.

Подробнее
25-04-2013 дата публикации

Detection of feline Immunodeficiency Virus

Номер: US20130101987A1
Принадлежит: Idexx Laboratories Inc

Method, device and kit for the detection of antibodies directed to Feline Immunodeficiency Virus (FIV). The method includes contacting the felid biological sample with FIV env polypeptide and detecting whether the polypeptide substantially binds to the antibody in the biological sample. The method will detect FIV antibodies in a sample from animals that have been naturally infected but the method will not detect antibodies in a sample from animals that have not been infected and that have not been vaccinated with an FIV vaccine after within about the previous five to eight weeks.

Подробнее
25-04-2013 дата публикации

Method of retrovirus storage

Номер: US20130102048A1
Принадлежит: Takara Bio Inc

A method of retrovirus storage, characterized in that a retrovirus is sustained in the presence of a substance with retrovirus binding activity immobilized on a solid phase. Further, there is provided a retrovirus composition characterized in that a retrovirus in the form of binding to a substance with retrovirus binding activity is sealed in a container holding a solid phase having the substance with retrovirus binding activity immobilized thereon.

Подробнее
25-04-2013 дата публикации

Multi Plasmid System For The Production Of Influenza Virus

Номер: US20130102053A1
Автор: Jin Hong, Lu Bin
Принадлежит: MEDIMMUNE, LLC

Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing influenza viruses with enhanced ability to replicate in embryonated chicken eggs and/or cells (e.g., Vero and/or MDCK) and further provides influenza viruses with enhanced replication characteristics. 1. A method of increasing replication of a reassortant influenza A virus by at least 10% , comprising:a) introducing an amino acid substitution to an HA amino acid sequence of the reassortant virus, thereby producing an altered reassortant virus, wherein the amino acid substitution is to threonine at position 196; andb) growing the altered reassortant virus in eggs.2. The method of claim 1 , wherein step a) comprises introducing a second amino acid substitution to the HA amino acid sequence of the reassortant virus claim 1 , wherein the second amino acid substitution is to valine at position 186.3. The method of claim 1 , wherein step a) comprises introducing a second amino acid substitution to the HA amino acid sequence of the reassortant virus claim 1 , wherein the second amino acid substitution is to isoleucine at position 226.4. The method of claim 2 , wherein step a) comprises introducing a third amino acid substitution to the HA amino acid sequence of the reassortant virus claim 2 , wherein the third amino acid substitution is to isoleucine at position 226.5. A replication enhanced reassortant influenza virus produced by the method of .6. A replication enhanced reassortant influenza virus produced by the method of .7. A replication enhanced reassortant influenza virus produced by the method of .8. A replication enhanced reassortant influenza virus produced by the method of .9. The method of claim 1 , wherein the reassortant influenza A virus grows to a titer of at ...

Подробнее
09-05-2013 дата публикации

SWINE INFLUENZA HEMAGGLUTININ VARIANTS

Номер: US20130115235A1
Автор: CHEN Zhongying, Jin Hong
Принадлежит: MEDIMMUNE, LLC

The technology relates in part to modified influenza viruses useful for vaccine development. Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided. 1. A reassortant influenza virus comprising a first genome segment encoding an isolated or recombinant polypeptide comprising an amino acid sequence selected from the group consisting of:(a) SEQ ID NO:1, or a fragment thereof;(b) a modified SEQ ID NO:1, wherein the amino acid at position 125 is substituted with a non-native amino acid, or a fragment thereof;(c) a modified SEQ ID NO: 1, wherein the amino acid at position 127 is substituted with a non-native amino acid, or a fragment thereof; and(d) a modified SEQ ID NO: 1, wherein the amino acid at position 125 is substituted with a non-native amino acid and the amino acid at position 127 is substituted with a non-native amino acid, or a fragment thereof.2. The reassortant influenza virus of claim 1 , wherein the amino acid sequence comprises amino acids 1-327 of SEQ ID NO:1 or amino acids 1-327 of a modified SEQ ID NO:1 according to (b) claim 1 , (c) or (d).3. The reassortant influenza virus of claim 1 , wherein the first genome segment produces a polynucleotide encoding the polypeptide claim 1 , wherein the polynucleotide comprises a nucleotide sequence of:(i) SEQ ID NO:2, or a fragment thereof, which encodes a polypeptide according to (a), or(ii) a modified SEQ ID NO:2, or a fragment thereof, which encodes a polypeptide according to (b), (c) or (d).4. The reassortant influenza virus of claim 1 , wherein:(i) the amino acid at position 125 of SEQ ID NO:1 is substituted with an aspartic acid (D) or a glutamic acid (E);(ii) the amino acid at position 127 of SEQ ID NO:1 is substituted with a glutamic acid (E); or(iii) the amino acid at position 125 of SEQ ID NO:1 is substituted with an aspartic acid (D) or a glutamic acid (E), and the amino acid at position 127 of SEQ ID NO:1 is ...

Подробнее
09-05-2013 дата публикации

PROPHYLAXIS AND TREATMENT OF PRDC

Номер: US20130115236A1
Принадлежит: Boehringer Ingelheim Vetmedica, Inc.

The present invention relates to the use of an immunogenic composition comprising a porcine circovirus type 2 (PCV2) antigen for the prevention and treatment, including a reduction in the severity of, duration of, and manifestations of, porcine respiratory disease complex (PRDC) in animals, preferably in pigs. 1. A method for the prophylaxis or treatment of porcine respiratory disease complex (PRDC) or one or more clinical signs of PRDC in a group of porcine , wherein said PRDC is caused by PCV2 and at least one other PRDC causing pathogen , wherein the method comprises administering to a porcine in need a therapeutically effective amount of recombinant PCV2 ORF2 protein or an immunogenic composition comprising recombinant PCV2 ORF2 protein , wherein the therapeutically effective amount of recombinant PCV2 ORF2 protein comprises about 4 μg to 400 μg of recombinant PCV2 ORF2 protein , and wherein the immunogenic composition comprising recombinant PCV2 ORF2 protein further comprises a polymer of acrylic or methacrylic acid.2. The method according to claim 1 , wherein the one or more clinical signs of PRDC are selected from the group consisting of cough claim 1 , dyspnea claim 1 , slow growth claim 1 , decreased feed efficiency claim 1 , lethargy claim 1 , anorexia claim 1 , and/or a marked increase in mortality in the middle to late phase of fattening.3. The method according to claim 2 , wherein the cough and dyspnea claim 2 , are refractory to antibiotic therapy.4. The method according to claim 1 , wherein the porcine belongs to a herd that is positive for PCV2.5Mycoplasma hyopneumoniae, Bordetella bronchisepticaMycoplasma hyorhinis, Streptococcus suisPasteurella multocida.. The method according to claim 1 , wherein the porcine belongs to a herd that is positive for PCV2 and one or more further pathogen(s) selected from the group consisting of PRRSV claim 1 , claim 1 , Swine influenza virus claim 1 , and/or6Mycoplasma hyopneumoniae, Bordetella ...

Подробнее
09-05-2013 дата публикации

Modified Viral Strains and Method for Improving the Production of Vaccine Seeds of Influenza Virus

Номер: US20130115242A1
Принадлежит:

Modified influenza A/PR/8/34 virus and reassortant influenza A/PR/8/34 virus including a modified PB1 gene and methods for improving the production of HA (hemagglutinin) and NA (neuraminidase) vaccine glycoproteins. 1. A modified influenza A/PR/8/34 virus , whose quantity of HA-NA (hemagglutinin and neuraminidase) glycoproteins on the surface is greater than 550 glycoproteins for a virion of 100 nm in diameter , including a mutated PB 1 gene of SEQ ID NO: 1 coding for a PB1 protein having at least two specific amino acid modifications selected from the group consisting of: 188 (K→E) , 205 (M→I) , 212 (L→V) , 216 (S→G) , 398 (E→D) , 486 (R→K) 563 (I→R) , 576 (I→L) , 581 (E→D) , 584 (R→Q) , 586 (K→R) , 617 (D→N) , 621 (Q→R) , 682 (V→I) and 691 (R→K).2. The modified influenza A/PR/8/34 virus according to claim 1 , wherein it includes a mutated PB1 gene of SEQ ID NO: 1 coding for a PB1 protein with at least both amino acid modifications 563 (I→R) and 682 (V→I).3. The modified influenza A/PR/8/34 virus according to claim 1 , wherein it includes the PB 1 gene of another strain of influenza A virus whose quantity of HA-NA surface glycoproteins is greater than 550 glycoproteins for a virion of 100 nm in diameter.4. The modified influenza A/PR/8/34 virus according to claim 1 , wherein it includes the PB1 gene of H3N2 influenza virus having the sequence of SEQ ID NO: 2.5. The modified influenza A/PR/8/34 virus according to claim 1 , wherein it is reassortant including the HA and NA genes of another influenza virus.6. The modified influenza A/PR/8/34 virus according to claim 5 , including the HA and NA genes of an influenza virus selected from the viruses having the H3N2 claim 5 , H2N2 claim 5 , H1N2 claim 5 , H5N2 claim 5 , H5N1 claim 5 , H7N7 claim 5 , H9N2 and H3N1 subtypes.7. A method for producing HA-NA vaccine glycoproteins of influenza virus claim 5 , wherein a modified influenza virus according to including the HA and NA genes coding for said HA-NA vaccine ...

Подробнее
09-05-2013 дата публикации

MODIFIED HUMAN HEPATITIS C VIRUS GENOMIC RNA THAT CAN BE AUTONOMOUSLY REPLICATED

Номер: US20130115592A1
Принадлежит:

The present invention provides modified hepatitis C virus genomic RNA, comprising nucleotide sequences of genomic RNA portions of two or more types of hepatitis C viruses, which comprises a 5′ untranslated region, a core protein coding sequence, an E1 protein coding sequence, a p7 protein coding sequence, an E2 protein coding sequence, an NS2 protein coding sequence, an NS3 protein coding sequence, an NS4A protein coding sequence, an NS4B protein coding sequence, an NS5A protein coding sequence, an NS5B protein coding sequence, and a 3′ untranslated region, and which can be autonomously replicated. In particular, the present invention relates to modified hepatitis C virus genomic RNA, which can be autonomously replicated by substitution of the RNA sequence portion encoding NS3, NS4, NS5A, and NS5B proteins of hepatitis C virus genomic RNA with a partial RNA sequence encoding NS3, NS4, NS5A, and NS5B proteins of a JFH1 strain shown in SEQ ID NO: 1. 1. A modified hepatitis C virus genomic RNA comprising genomic RNA portions of two or more strains of hepatitis C viruses , which comprises a 5′ untranslated region , a core protein coding sequence , an E1 protein coding sequence , an E2 protein coding sequence , a p7 protein coding sequence , an NS2 protein coding sequence , a partial RNA sequence encoding NS3 , NS4A , NS4B , NS5A , and NS5B proteins of a JFH1 strain shown in SEQ ID NO:1 , and a 3′ untranslated region , wherein said modified hepatitis C virus genomic RNA is autonomously replicated and is capable of producing infectious hepatitis C virus particles in a cultured cell system , wherein the core protein coding sequence , the E1 protein coding sequence , the E2 protein coding sequence , and the p7 protein coding sequence are from the hepatitis C virus strain of genotype 1b , wherein the NS2 protein coding sequence is from the hepatitis C virus strain selected from the group consisting of genotype 1b and genotype 2a , and wherein the 5′ untranslated region and ...

Подробнее
23-05-2013 дата публикации

MODIFIED INFECTIOUS LARYNGOTRACHEITIS VIRUS (ILTV) AND USES THEREOF

Номер: US20130129780A1

Provided herein are modified infectious largotracheitis viruses (ILTVs) and methods of using the same. For example, provided are attenuated ILTVs. The attenuated ILTVs can be used to illicit immune responses in avian species. Optionally, the attenuated ILTVs can be used to vaccinate an avian subject or a population of avian subjects. Optionally, an attenuated ILTV is administered in ovo to an avian egg. One or more such in ovo administration can be used to increase the immunity of an avian herd. 1. A composition comprising an attenuated infectious laryngotracheitis virus (ILTV) comprising a glycoprotein J mutation , wherein the mutation inhibits expression of glycoprotein J.2. The composition of claim 1 , wherein the attenuated ILTV comprises USDA challenge strain USDA-ch.3. The composition of claim 1 , wherein the mutation inhibits the expression of glycoprotein J protein.4. The composition of claim 3 , wherein the mutation comprises a glycoprotein J promoter element mutation and wherein the mutation inhibits a function of the promoter element.5. The composition of claim 1 , wherein the mutation comprises a deletion of a glycoprotein J nucleotide sequence.6. The composition of claim 5 , wherein the mutation comprises a complete or partial deletion of SEQ ID NO:1.7. The composition of claim 6 , wherein the mutation comprises a deletion of nucleotides 1-2291 of SEQ ID NO:1.8. The composition of claim 6 , wherein a reporter protein expression cassette is inserted at the point of the deletion.9. The composition of claim 8 , wherein the reporter protein is green-fluorescent protein.10. The composition of claim 6 , wherein the mutation comprises a deletion of nucleotides 1-2188 of SEQ ID NO:1.11. The composition of claim 10 , wherein a reporter protein expression cassette is inserted at the point of the deletion.12. The composition of claim 11 , wherein the reporter protein is green-fluorescent protein.13. The composition of claim 10 , wherein a viral protein expression ...

Подробнее
23-05-2013 дата публикации

Method and system of particle-phage epitope complex

Номер: US20130130355A1
Принадлежит: Armune Biosciences Inc

The present disclosure provides compositions and methods for using phage epitopes to profile the immune response. The phage epitopes can be used to detect one or more antibodies from a sample. Furthermore, the present disclosure provides methods and compositions for detecting a cancer based on the detection of one or more antibodies. In one embodiment, the antibody is an autoantibody. The present disclosure also provides methods of producing antibody detecting complexes.

Подробнее
30-05-2013 дата публикации

Immunostimulating Polyphosphazene Compounds

Номер: US20130136758A1
Принадлежит: Individual

Polyphosphazene polymers having immunomodulating activity, and the biomedical use of such polyphosphazene polymers, in conjunction with an antigen or an immunogen are disclosed.

Подробнее
30-05-2013 дата публикации

Compositions, methods and uses for poxvirus elements in vaccine constructs

Номер: US20130136767A1
Принадлежит: Inviragen Inc

Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing poxvirus constructs. In some embodiments, constructs may contain an influenza virus gene segment. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, poxvirus vaccine compositions. In other embodiments, vaccine compositions are reported of use in a subject.

Подробнее
30-05-2013 дата публикации

Recombinant HCMV and RHCMV vectors and uses thereof

Номер: US20130136768A1
Принадлежит: OREGON HEALTH & SCIENCE UNIVERSITY

Described herein are recombinant rhesus cytomegalovirus (RhCMV) and human cytomegalovirus (HCMV) vectors encoding heterologous antigens, such as pathogen-specific antigens or tumor antigens. The recombinant vectors elicit and maintain high level cellular and humoral immune responses specific for the heterologous antigen. The recombinant RhCMV and HCMV vectors may be used, for example, for the treatment or prevention of infectious disease or cancer. In some examples, the recombinant RhCMV or HCMV vectors may include deletions in genes encoding immunomodulatory proteins. In some examples, the recombinant RhCMV or HCMV vectors may be deficient or impaired in their ability to replicate within a cell, disseminate within the host or spread among hosts by including a deletion in one or more genes essential or augmenting for CMV replication, dissemination or spread. 1. A recombinant RhCMV or HCMV vector comprising a nucleic acid sequence encoding a heterologous antigen , wherein the heterologous antigen is a human pathogen-specific antigen or a tumor antigen.2PlasmodiumMycobacterium tuberculosisClostridium tetani.. The recombinant RhCMV or HCMV vector of claim 1 , wherein the human pathogen-specific antigen is isolated from human immunodeficiency virus (HIV) claim 1 , simian immunodeficiency virus (SIV) claim 1 , human cytomegalovirus (HCMV) claim 1 , hepatitis C claim 1 , papillomavirus claim 1 , claim 1 , Kaposi's sarcoma associated herpesvirus claim 1 , Varicella zoster virus claim 1 , Ebola virus claim 1 , claim 1 , Chikungunya virus claim 1 , dengue virus claim 1 , monkeypox virus claim 1 , herpes simplex 1 claim 1 , herpes simplex 2 claim 1 , Epstein-Barr virus (EBV) claim 1 , poliovirus claim 1 , influenza virus or3. The recombinant RhCMV vector of claim 1 , comprising the nucleic acid sequence of SEQ ID NO: 1.4. The recombinant RhCMV or HCMV vector of claim 1 , comprising a deletion of US2 claim 1 , US3 claim 1 , US6 or US11 or a homolog thereof.5. The recombinant ...

Подробнее
30-05-2013 дата публикации

Biomatrix Scaffolds for Industrial Scale Dispersal

Номер: US20130137176A1

The present invention provides biomatrix scaffolds for industrial scale dispersal.

Подробнее
30-05-2013 дата публикации

B-CELL STIMULATING FUSION PROTEINS OF AN ANTIGEN WITH BAFF OR APRIL

Номер: US20130139274A1
Автор: Sanders Rogier Willem

The invention relates to the fields of molecular biology, medicine, virology and vaccine development. Because the different forms of the presently available vaccines all have their specific drawbacks, there is a need for alternative vaccine strategies. The current invention provides means and methods for such alternative vaccine strategies. 1. A fusion protein comprising an antigen and a ligand capable of inducing , enhancing or sustaining a B cell immune response , wherein said ligand is selected from the group consisting of a compound comprising at least the extracellular domain of a proliferation inducing ligand (APRIL) , and a compound comprising an amino acid sequence having at least 80% sequence identity with at least the extracellular domain of APRIL.2. A fusion protein comprising an antigen and a polypeptide comprising an amino acid sequence having at least 80% sequence identity with a cytokine capable of inducing or sustaining a B cell immune response.3. A fusion protein according to claim 2 , wherein said antigen comprises an amino acid sequence with a length of at least 300 amino acids with at least 80% sequence identity to a gp120 protein and/or a gp160 protein of HIV envelope glycoprotein complex (Env) claim 2 , wherein at least 5 amino acids of the V1 loop and/or at least 5 amino acids of the V2 loop of said gp120 molecule are absent claim 2 , and wherein at the deletion site in V1 and/or at the deletion site in V2 claim 2 , said polypeptide is inserted.4. A fusion protein according to claim 2 , wherein said cytokine is GMCSF or IL-21.5. A fusion protein according to claim 1 , wherein said antigen comprises a pathogenic protein claim 1 , optionally a virus protein claim 1 , or an immunogenic part thereof claim 1 , said antigen optionally having at least 80% sequence identity with a virus protein of HIV claim 1 , influenza virus or Ebola virus claim 1 , or with an immunogenic part thereof.6. A fusion protein according to claim 1 , further comprising a ...

Подробнее
06-06-2013 дата публикации

Hapten-Carrier Conjugates and Uses Thereof

Номер: US20130142821A1
Принадлежит: Cytos Biotechnology AG

The present invention provides compositions comprising a conjugate of a hapten with a carrier in an ordered and repetitive array, and methods of making such compositions. The conjugates and compositions of the invention may comprise a variety of haptens, including hormones, toxins and drugs, especially drugs of addiction such as nicotine. Compositions and conjugates of the invention are useful for inducing immune responses against haptens, which can use useful in a variety of therapeutic, prophylactic and diagnostic regimens. In certain embodiments, immune responses generated using the conjugates, compositions and methods of the present invention are useful to prevent or treat addiction to drugs of abuse and the resultant diseases associated with drug addiction.

Подробнее
06-06-2013 дата публикации

CMV GLYCOPROTEINS AND RECOMBINANT VECTORS

Номер: US20130142823A1
Принадлежит: Oregon Health and Science University

This invention also relates to recombinant vectors expressing one or more of the human CMV (HCMV) glycoproteins US2, US3, US6 and US11 or corresponding functional rhesus CMV (RhCMV) homologues Rh182, Rh184, Rh185 or Rh189, methods of making them, uses for them, expression products from them, and uses for the expression products. This invention also relates to recombinant cytomegalovirus vectors vectors lacking one or more of the glycoproteins, methods of making them, uses for them, expression products from them, and uses for the expression products. 1. A method to enable superinfection or repeated infection of an animal by a vector containing and expressing at least one cytomegalovirus (CMV) glycoprotein , wherein the glycoprotein is US2 , US3 , US6 or US11 of human CMV (HCMV) or the corresponding functional homologues Rh182 , Rh184 , Rh185 or Rh189 of rhesus CMV (RhCMV) , and administering the vector into the animal , wherein the vector expresses at least one cytomegalovirus glycoprotein.2. The method of claim 1 , wherein the vector is a viral vector.3. The method of claim 2 , wherein the vector is an adenovirus vector claim 2 , adeno-associated virus (AAV) vector claim 2 , alphavirus vector claim 2 , herpesvirus vector claim 2 , retrovirus vector or poxvirus vector4. The method of claim 1 , wherein the vector contains and expresses US2 claim 1 , US3 claim 1 , US6 and US11 of HCMV claim 1 , or Rh182 claim 1 , Rh184 claim 1 , Rh185 and Rh189 of RhCMV.5. The method of claim 1 , wherein the vector contains and expresses all of the glycoproteins within the US2 to US11 region of HCMV or Rh182 to Rh189 region of RhCMV.6. A method of determining efficacy of a CMV vaccine claim 1 , comprising (a) administering a CMV vaccine to a test subject claim 1 , (b) challenging the test subject with a CMV vector claim 1 , wherein glycoproteins within the US2 to US11 region of CMV are deleted from the CMV vector claim 1 , and wherein the CMV vector contains and expresses at least one ...

Подробнее
06-06-2013 дата публикации

Novel modified live-attenuated vaccines (mlv) created by dna shuffling against porcine reproductive and respiratory syndrome virus (prrsv)

Номер: US20130142824A1

The present invention provides a novel infectious cDNA clone of porcine reproductive and respiratory syndrome virus (PRRSV), particularly for PRRSV strain VR2385; an improved DNA-launched reverse genetics system for PRRSV; infectious chimeric PRRSV viruses generated through DNA shuffling; modified live- attenuated virus vaccines (MLV) using DNA shuffled chimeric viruses; chimeric viral proteins produced through shuffled chimeric viruses; PRRSV antigens and subunit vaccines based on shuffled chimeric viral proteins; and method of producing broadly protective PRRSV vaccines using DNA shuffling techniques. Particularly, the present invention provides infectious chimeric viruses generated by DNA shuffling of the GP5 genes of genetically distinct strains of PRRSV; modified live-attenuated vaccines comprise infectious chimeric viruses containing the shuffled GP5 genes and/or other shuffled PRRSV proteins (such as GP2, GP3, GP4, M, and non-structural proteins); broadly -protective subunit vaccines comprising PRRSV chimeric shuffled GP5 protein and/or other shuffled PRRSV proteins (such as GP2, GP3, GP4, M, and non-structural proteins).

Подробнее
06-06-2013 дата публикации

IN VIVO TARGETING OF DENDRITIC CELLS

Номер: US20130142864A1
Принадлежит: Lipotek Pty Ltd.

The invention provides a composition for modulating immunity by the in vivo targeting of an antigen to dendritic cells. The composition comprises: a preparation of antigen-containing membrane vesicles or antigen-containing liposomes which have on their surfaces a plurality of metal chelating groups; and, a ligand for a receptor on the dendritic cells, the ligand being linked to a metal chelating group via a metal affinity tag on the ligand. The composition further includes an immunomodulatory factor. A process for preparing the composition is also provided. The invention further provides a method of modulating an immune disorder, and methods of treating tumours and infections. 1. A composition for modulating immunity by the in vivo targeting of an antigen to dendritic cells , the composition comprising:a preparation of antigen-containing membrane vesicles or antigen-containing liposomes having on the surface thereof a plurality of metal chelating groups comprising nitrilotriacetic acid headgroups of (tri(nitrilotriacetic acid) ditetradecylamine) present within phospholipids and/or lipids comprising the vesicles or liposomes; anda ligand selected from the group consisting of an antibody, an antibody fragment, and a domain antibody, which can specifically bind a receptor on said dendritic cells, said ligand being linked to a said metal chelating group via a metal affinity tag on said ligand; wherein, said antigen-containing vesicles or liposomes include interferon-γ, and wherein the antigen of said antigen-containing vesicles or liposomes is not covalently linked to the interferon-γ.2. The composition according to claim 1 , wherein said antigen-containing membrane vesicles are selected from the group consisting of tumour-derived plasma membrane vesicles claim 1 , lymphocyte-derived plasma membrane vesicles claim 1 , leucocyte-derived plasma membrane vesicles claim 1 , and membranous preparations of bacteria claim 1 , protozoa claim 1 , viruses or fungi.3. The ...

Подробнее
06-06-2013 дата публикации

Bionanomaterials and Their Synthesis

Номер: US20130143303A1
Автор: Niu Zhongwei, WANG Qian
Принадлежит: UNIVERSITY OF SOUTH CAROLINA

The use of biomaterials, such as viruses and virus-like particles, to form nanostructures is generally disclosed. For instance, rod-like viruses can be used to form composite nanofibers that are fixed together in a head-to-tail assembly by a polymer. Also, 2-dimensional nanostructures formed from crosslinked viruses assembled in a single, film-like layer are generally disclosed. Porous gels having controllable pore size through the use of virus particles are also disclosed. 1. A 1-dimensional composite nanofiber comprising:a plurality of functionalized rod-like viruses, wherein each functionalized rod-like virus defines a head and a tail, and wherein the plurality of functionalized rod-like viruses are assembled in a wire-like structure such that the head of one functionalized rod-like virus is adjacent to the tail of an adjacent virus, wherein the functionalized rod-like viruses comprise alkyne-functional rod-like viruses; anda polymer surrounding the wire-like structure to fix the plurality of rod-like viruses together in the wire-like structure.2. The composite nanofiber as in claim 1 , wherein the polymer comprises a plurality of positively charged monomers.3. The composite nanofiber as in claim 1 , wherein the polymer comprises a plurality of monomers having an amino group.4. The composite nanofiber as in claim 1 , wherein the polymer comprises aniline monomers.5. The composite nanofiber as in claim 1 , wherein the polymer comprises polyaniline.6. The composite nanofiber as in claim 1 , wherein the polymer comprises polyaniline claim 1 , polypyrole claim 1 , polythiophene claim 1 , polyethylenedioxythiophene claim 1 , polypyrazole claim 1 , or derivatives or copolymers thereof.7. A two-dimensional nanostructure comprising:a plurality of viruses assembled in a single layer, wherein said plurality of viruses are crosslinked to fix the single layer into the two-dimensional nanostructure.8. A two-dimensional nanostructure as in claim 7 , wherein said plurality of ...

Подробнее
13-06-2013 дата публикации

Organic peroxide compounds for microorganism inactivation

Номер: US20130149194A1
Принадлежит: Individual

Multifunctional organic peroxides are used as microbiological inactivators and/or for degrading nucleic acids. These include at least one carbon atom and at least two organic peroxide groups. The inactivator is ideally a hydroperoxide. The invention is particularly useful during preparation of viral vaccines.

Подробнее
13-06-2013 дата публикации

CHIMERIC INFECTIOUS DNA CLONES, CHIMERIC PORCINE CIRCOVIRUSES AND USES THEREOF

Номер: US20130149334A1
Принадлежит:

The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric infectious DNA clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic PCV1 in which the immunogenic ORF gene of the pathogenic PCV2 replaces a gene of the nonpathogenic PCV1, preferably in the same position. The chimeric virus advantageously retains the nonpathogenic phenotype of PCV1 but elicits specific immune responses against the pathogenic PCV2. The invention further embraces the immunogenic polypeptide expression products. In addition, the invention encompasses two mutations in the PCV2 immunogenic capsid gene and protein, and the introduction of the ORF2 mutations in the chimeric clones. 114-. (canceled)15. A vaccine comprising a nontoxic , physiologically acceptable carrier and an immunogenic amount of a member selected from the group consisting of:(a) a PCV2 molecular DNA clone having ATCC Patent Deposit Designation PTA-3913 or a PCV2 DNA clone derived therefrom; and(b) a plasmid or viral vector containing the PCV2 molecular DNA clone having ATCC Patent Deposit Designation PTA-3913 or the PCV2 DNA clone derived therefrom.1618-. (canceled)19. A method of protecting a pig against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2 comprising administering to the pig in need of protection an immunologically effective amount of the vaccine according to .20. (canceled)21. The method according to claim 19 , which comprises administering the vaccine parenterally claim 19 , intranasally claim 19 , intradermally or transdermally to the pig.22. The method according to claim 21 , which comprises administering the vaccine intralymphoidly or intramuscularly to the pig.2328-. (canceled)29. A PCV2 molecular DNA clone having ATCC Patent Deposit ...

Подробнее
13-06-2013 дата публикации

COMPOSITIONS AND METHODS FOR RAPID IMMUNIZATION AGAINST DENGUE VIRUS

Номер: US20130149338A1
Принадлежит:

Embodiments of the present invention report compositions and methods for vaccinating a subject against all dengue virus serotypes. In some embodiments, multiple vaccine compositions may be administered to a subject in different anatomical locations in order to induce a rapid response to all dengue virus serotypes. In certain embodiments, administration of two or more vaccine compositions to a subject against all dengue virus serotypes may include two or more routes of administration. 1. A method for rapid induction of neutralizing antibodies in a subject against three or more dengue virus serotypes , comprising , administering two or more doses of a single formulation of a live , attenuated dengue virus vaccine to a subject at two or more anatomical locations on the same day , inducing neutralizing antibodies in the subject against three or more dengue virus serotypes.2. The method of , further comprising administering at least one additional booster administration of a formulation of a live , attenuated dengue vaccines 1 to 180 days after the simultaneous administrations of .3. The method of claim 1 , wherein the single formulation of a live claim 1 , attenuated dengue vaccine comprises a multivalent composition with a predetermined ratio of monovalent vaccines for three or more dengue virus serotypes in a single composition.4. The method of claim 1 , wherein the single formulation of a live claim 1 , attenuated dengue vaccine comprises a multivalent composition with equivalent ratios of monovalent vaccines for three or more dengue virus serotypes in a single composition.5. The method of claim 1 , wherein the formulation of a live claim 1 , attenuated dengue vaccine used for at least one additional booster administration is identical to the formulation used for the same day administrations of .6. The method of claim 1 , wherein the formulation of a live claim 1 , attenuated dengue vaccine used for at least one additional booster administration is different than the ...

Подробнее
20-06-2013 дата публикации

IDENTIFICATION OF PROTECTIVE ANTIGENIC DETERMINANTS OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS AND USES THEREOF

Номер: US20130156800A1

The invention relates to a polypeptide of a protective antigenic determinant (PAD polypeptide) of porcine reproductive and respiratory syndrome virus (PRRSV) and nucleic acids encoding a PAD polypeptide. The PAD polypeptide and nucleic acids encoding a PAD polypeptide are useful in the development of antibodies directed to PAD, vaccines effective in providing protection against PRRSV infection, and diagnostic assays detecting the presence of PAD antibodies generated by a PAD-specific vaccine. The invention also discloses methods of generating antibodies to PAD, for vaccinating a pig to provide protection from PRRSV infections, a method of preparing the vaccine, a method of treating PRRSV infections in a pig, and a method of detecting antibodies to PAD of PRRSV. 1. A method for treating a PRRSV infection in a pig comprising:administering to said pig a therapeutically effective amount of the vaccine of comprising a first GP5-M heterodimer, wherein the GP5 of the first GP5-M heterodimer has glycosylation at position 44 of the GP5 in a North American (NA) PRRSV or glycosylation at position 46 of the GP5 in a European (EU) PRRSV; andadministering to the animal a second GP5-M heterodimer, wherein the GP5 of the second GP5-M heterodimer does not have glycosylation at position 44 of GP5 in a North American (NA) PRRSV or at position 46 of the GP5 in a European (EU) PRRSV, thereby treating a PRRSV infection in a pig2. A multivalent vaccine comprising GP5-M protein heterodimers of PRRSV a polypeptide comprising:a sequence comprising a heterodimer of a matrix protein (M protein) of porcine reproductive and respiratory syndrome virus (PRRSV) and a glycoprotein 5 (GP5) of PRRSV, wherein said GP5 protein has N-glycosylation of asparagine amino acids located at position 44 of the GP5 protein in North American PRRSV strains or at position 46 of the GP5 protein in European PRRSV strains; anda sequence comprising a heterodimer of a matrix protein (M protein) of porcine reproductive ...

Подробнее
20-06-2013 дата публикации

Recombinant Bacterium and Uses Thereof

Номер: US20130156809A1
Принадлежит:

The present invention relates to a recombinant bacterium expressing an antigen that is translocated to the cytosol of a host organism, and uses thereof. To this end, the present invention provides a recombinant bacterium comprising a nucleic acid encoding an antigen that is translocated to the cytosol of a host cell utilizing Type III secretion system. The recombinant bacterium is generally chosen from intracellular pathogens that reside in the phagosome and fail to induce rapid T cell activation. The translocated antigen may be a viral antigen, a bacterial antigen, or a tumour antigen. Methods of imparting immunity using the recombinant bacterium are also provided. 1. A recombinant bacterium , comprising a nucleic acid encoding an antigen that is translocated to the cytosol of a host cell.2Salmonella, Mycobacteria, Brucella,Leishmania.. The recombinant bacterium of claim 1 , wherein the bacterium is an intracellular bacterium such as or3Salmonella.. The recombinant bacterium of claim 1 , wherein the bacterium is4. The recombinant bacterium of claim 1 , wherein the antigen is a viral antigen claim 1 , a bacterial antigen claim 1 , or a tumour antigen.5. The recombinant bacterium of claim 1 , wherein the antigen is a fusion protein comprising an antigen and a translocation domain from a type III secretion system.6. The recombinant bacterium of claim 5 , wherein the translocation protein is YopE claim 5 , SopE claim 5 , SptP claim 5 , or a fragment thereof.7. The recombinant bacterium of claim 5 , wherein the fusion protein further comprises a chaperone.8. The recombinant bacterium of claim 7 , wherein the chaperone is derived from type Ill secretion systems.9. The recombinant bacterium of claims 8 , wherein the chaperone is SycE or HSP70.10. The recombinant bacterium of claim 1 , wherein the nucleic acid is comprised in a vector.11. The recombinant bacterium of claim 10 , wherein the vector is a pHR vector.12. The recombinant bacterium of claim 10 , wherein the ...

Подробнее
20-06-2013 дата публикации

Method for simultaneously detecting an antigen of, and an antibody against, an infectious microorganism

Номер: US20130157255A1
Принадлежит: Bio Rad Innovations SAS

The invention relates to a method for detecting, in vitro, an infection with a microorganism, such as the hepatitis C virus, in a biological sample, by simultaneously detecting an antigen of this microorganism and the antibodies against this same antigen, and also to the reagents and kits implementing this method.

Подробнее
20-06-2013 дата публикации

Optimized promoter sequence

Номер: US20130158246A1

A modified CAG promoter which is capable of driving high levels of expression of sequences of interest inserted downstream therefrom is herein described.

Подробнее